This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brunelle, M. N.
Right arrow Articles by Zoulim, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunelle, M. N.
Right arrow Articles by Zoulim, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 2240-2243, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01440-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants{triangledown}

M. N. Brunelle,1,2,3 J. Lucifora,1,2,3 J. Neyts,4 S. Villet,1,2,3 A. Holy,5 C. Trepo,1,2,3,6 and F. Zoulim1,2,3,6*

INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France,1 Université Lyon 1, 69008 Lyon, France,2 IFR62 Lyon Est, Faculté de Médecine Laennec, 69008 Lyon, France,3 Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium,4 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic,5 Hospices Civils de Lyon, Hôtel Dieu Hospital, 69002 Lyon, France6

Received 17 November 2006/ Returned for modification 8 January 2007/ Accepted 9 March 2007

The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.

* Corresponding author. Mailing address: INSERM, U871, 151 Cours Albert Thomas, 69424 Lyon cedex 03, France. Phone: 33 4 72 68 19 70. Fax: 33 4 72 68 19 71. E-mail: zoulim{at}lyon.inserm.fr

{triangledown} Published ahead of print on 19 March 2007.

Antimicrobial Agents and Chemotherapy, June 2007, p. 2240-2243, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01440-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas, O. O., Shiffman, M. L., Trinh, H., Washington, M. K., Sorbel, J., Anderson, J., Snow-Lampart, A., Mondou, E., Quinn, J., Rousseau, F. (2008). Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. NEJM 359: 2442-2455 [Abstract] [Full Text]  
  • Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»